Live Breaking News & Updates on Platinum Resistant Ovarian Cancer

Stay updated with breaking news from Platinum resistant ovarian cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Maria Koehler , Drug Administration , Company Nasdaq , Repare Therapeutics Inc , Platinum Resistant Ovarian Cancer , Fast Track , Executive Vice President , Chief Medical Officer , Fast Track Designation ,

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 . ....

United States , North Carolina , Mirvetuximab Soravtansine , Conor Richardson , Clay Siegall , Kate Sasser , Taylor Schreiber , Exchange Commission , Ono Pharmaceutical Co Ltd , Development Rd Expenses , Shattuck Labs Inc , American Association For Cancer Research , Cancer Research , Annual Meeting , Chief Executive Officer , Ono Pharma , Milestones Expected , Platinum Resistant Ovarian Cancer , Cancer Cell , Ono Enter , Collaboration Agreement , Appoints Clay Siegall , Cash Equivalents , Clinical Trial , Shattuck Labs , Agonist Redirected Checkpoint ,

Dr Konecny on the FDA Approval of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer. ....

United States , Los Angeles , Gottfriede Konecny , University Of California , Department Of Medicine , Boxed Warning , Fda Approval Of Mirvetuximab Soravtansine , Patients With Frα Positive , Platinum Resistant Ovarian Cancer ,

Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers -March 12, 2024 at 08:08 am EDT

Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers -March 12, 2024 at 08:08 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , San Carlos , Floortje Backes , Adam Elnaggar , Michael Toboni , Sarah Lee , Anne Knisely , Natera Inc , Society Of Gynecologic Oncology , Clinical Laboratory Improvement Amendments , Gynecologic Oncology , Annual Meeting , Drive Purpose , Ovarian Cancer , Molecular Mirrors , Mike Shalamov , Gynecologic Cancers , Uterine Cancer , Monitoring Utilizing , Early Stage Uterine Cancer , Metastatic Endometrial Cancer , Platinum Resistant Ovarian Cancer ,

#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival

1. Mirvetuximab soravtansine-gynx (MIRV) significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant, folate receptor alpha (FRα)-positive ovarian cancer 2. Ocular adverse events were more common with MIRV, which included blurry vision, keratopathy, and dry eyes. Evidence Rating: Level 1 (Excellent) Study rundown: Mirvetuximab soravtansine-gynx (MIRV), is an antibody–drug conjugate ....

Minute Medicine Inc , Folate Receptor A , Mirv Therapy , Mirvetuximab Soravtansine Gynx , Ovarian Cancer , Platinum Resistant Ovarian Cancer ,